FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1510470871> ?p ?o ?g. }

• W1510470871 abstract "Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CABackground: Transitional cell carcinoma of the bladder (TCC) arises from the cells lining the bladder and accounts for 90% of bladder cancers. Current standard of care for muscle-invasive TCC is surgery with perioperative cisplatin-based chemotherapy regimens. Some tumors are quite sensitive to cisplatin but others either acquire resistance or are refractory. A reduced drug availability, an increased efficacy of the DNA damage repair machinery or defects in the apoptotic process are the main mechanisms involved in cisplatin resistance. The Hippo tumor suppressor pathway controls multiple cellular functions that are important for tumorigenesis and drug-resistance, including proliferation, apoptosis and oxidative stress regulation. Specifically, the overexpression of Yes-associated protein (YAP), one of the two repressed-targets of this pathway, prevents tumor necrosis factor-induced apoptosis in mouse liver and protects cancer cells from chemotherapy-induced apoptosis. Intriguingly, this transcriptional co-activator has been shown to be involved in bladder cancer progression and to be a biomarker for poor prognosis of patients with TCC. Furthermore, in ovarian cancer, YAP has been shown to confer resistance to cisplatin. Thus, we hypothesized that YAP may be involved in cisplatin resistance in bladder cancer and could predict drug response in TCC patients. Methods: Cisplatin activity and YAP protein expression and localization were analyzed in different in vitro and in vivo models of TCC: 1) Collection of bladder cancer cell lines, genetically manipulated by knocking-down or overexpressing YAP; 2) Cell line models of cisplatin resistance, obtained by long term continuous in vitro exposure to increasing drug concentrations; 3) Two TCC patient derived xenograft (PDX) models and derived primary cells (RP-B-01 and RP-B-02) with different intrinsic sensitivity to cisplatin. Furthermore, by continuous in vivo cisplatin treatment (2.5 to 5 mg/Kg, 1x/week, i.p.), we are currently establishing a cisplatin resistant RP-B-02 model. In vitro cisplatin effect was evaluated in apoptosis, proliferation and colony formation assays. Results: YAP expression and nuclear localization was inversely correlated with cisplatin sensitivity in TCC cell lines. Cisplatin-resistant TCC cell lines expressed higher YAP than parental counterparts. Cisplatin-induced apoptosis was significantly increased by YAP knockdown in T24 cell line. In vivo cisplatin treatment showed a greater anti-tumor effect in the low YAP-expressing RP-B-02 model as compared to the high YAP-expressing RP-B-01 tumors. Expression of YAP in human TCC specimens will be also presented. Summary: Overall, these data suggest that YAP has a role in bladder cancer response to cisplatin and highlights the potential therapeutic application of YAP as a biomarker of cisplatin sensitivity in TCC patients.Citation Format: Eric Stefano Ciamporcero, He Shen, Sreenivasulu Chintala, Swathi Ramakrishnan, Sheng Yu Ku, Kiersten M. Miles, Stefania Pizzimenti, Candace Johnson, Jianmin Zhang, Giuseppina Barrera, Roberto Pili. Hippo pathway effector Yes-associated protein and cisplatin resistance in transitional cell carcinoma of the bladder. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3754. doi:10.1158/1538-7445.AM2014-3754" @default.
• W1510470871 created "2016-06-24" @default.
• W1510470871 creator A5003107448 @default.
• W1510470871 creator A5023015562 @default.
• W1510470871 creator A5031047837 @default.
• W1510470871 creator A5031383735 @default.
• W1510470871 creator A5043387826 @default.
• W1510470871 creator A5051726130 @default.
• W1510470871 creator A5066492622 @default.
• W1510470871 creator A5072996841 @default.
• W1510470871 creator A5079156452 @default.
• W1510470871 creator A5081220639 @default.
• W1510470871 creator A5087493522 @default.
• W1510470871 date "2014-09-30" @default.
• W1510470871 modified "2023-09-26" @default.
• W1510470871 title "Abstract 3754: Hippo pathway effector Yes-associated protein and cisplatin resistance in transitional cell carcinoma of the bladder" @default.
• W1510470871 doi "https://doi.org/10.1158/1538-7445.am2014-3754" @default.
• W1510470871 hasPublicationYear "2014" @default.
• W1510470871 type Work @default.
• W1510470871 sameAs 1510470871 @default.
• W1510470871 citedByCount "0" @default.
• W1510470871 crossrefType "proceedings-article" @default.
• W1510470871 hasAuthorship W1510470871A5003107448 @default.
• W1510470871 hasAuthorship W1510470871A5023015562 @default.
• W1510470871 hasAuthorship W1510470871A5031047837 @default.
• W1510470871 hasAuthorship W1510470871A5031383735 @default.
• W1510470871 hasAuthorship W1510470871A5043387826 @default.
• W1510470871 hasAuthorship W1510470871A5051726130 @default.
• W1510470871 hasAuthorship W1510470871A5066492622 @default.
• W1510470871 hasAuthorship W1510470871A5072996841 @default.
• W1510470871 hasAuthorship W1510470871A5079156452 @default.
• W1510470871 hasAuthorship W1510470871A5081220639 @default.
• W1510470871 hasAuthorship W1510470871A5087493522 @default.
• W1510470871 hasConcept C121608353 @default.
• W1510470871 hasConcept C126322002 @default.
• W1510470871 hasConcept C190283241 @default.
• W1510470871 hasConcept C2776694085 @default.
• W1510470871 hasConcept C2778065480 @default.
• W1510470871 hasConcept C2778239845 @default.
• W1510470871 hasConcept C2780352672 @default.
• W1510470871 hasConcept C31573885 @default.
• W1510470871 hasConcept C502942594 @default.
• W1510470871 hasConcept C55493867 @default.
• W1510470871 hasConcept C555283112 @default.
• W1510470871 hasConcept C71924100 @default.
• W1510470871 hasConcept C86803240 @default.
• W1510470871 hasConceptScore W1510470871C121608353 @default.
• W1510470871 hasConceptScore W1510470871C126322002 @default.
• W1510470871 hasConceptScore W1510470871C190283241 @default.
• W1510470871 hasConceptScore W1510470871C2776694085 @default.
• W1510470871 hasConceptScore W1510470871C2778065480 @default.
• W1510470871 hasConceptScore W1510470871C2778239845 @default.
• W1510470871 hasConceptScore W1510470871C2780352672 @default.
• W1510470871 hasConceptScore W1510470871C31573885 @default.
• W1510470871 hasConceptScore W1510470871C502942594 @default.
• W1510470871 hasConceptScore W1510470871C55493867 @default.
• W1510470871 hasConceptScore W1510470871C555283112 @default.
• W1510470871 hasConceptScore W1510470871C71924100 @default.
• W1510470871 hasConceptScore W1510470871C86803240 @default.
• W1510470871 hasLocation W15104708711 @default.
• W1510470871 hasOpenAccess W1510470871 @default.
• W1510470871 hasPrimaryLocation W15104708711 @default.
• W1510470871 hasRelatedWork W1499327876 @default.
• W1510470871 hasRelatedWork W1513191530 @default.
• W1510470871 hasRelatedWork W1608238269 @default.
• W1510470871 hasRelatedWork W2005613545 @default.
• W1510470871 hasRelatedWork W2025119327 @default.
• W1510470871 hasRelatedWork W2058879280 @default.
• W1510470871 hasRelatedWork W2299200936 @default.
• W1510470871 hasRelatedWork W2320061024 @default.
• W1510470871 hasRelatedWork W2338612888 @default.
• W1510470871 hasRelatedWork W2468906605 @default.
• W1510470871 hasRelatedWork W2738617126 @default.
• W1510470871 hasRelatedWork W2739678278 @default.
• W1510470871 hasRelatedWork W2770793171 @default.
• W1510470871 hasRelatedWork W2809736037 @default.
• W1510470871 hasRelatedWork W2950071764 @default.
• W1510470871 hasRelatedWork W2985007742 @default.
• W1510470871 hasRelatedWork W3000926029 @default.
• W1510470871 hasRelatedWork W3033672408 @default.
• W1510470871 hasRelatedWork W3126827277 @default.
• W1510470871 hasRelatedWork W3171786802 @default.
• W1510470871 isParatext "false" @default.
• W1510470871 isRetracted "false" @default.
• W1510470871 magId "1510470871" @default.
• W1510470871 workType "article" @default.